National HealthCare Corporation
AMEX:NHCMedical - Care Facilities
+$1.33 today
- Market cap
- $3.16B
- Beta
- 0.67
- P/E (TTM)
- 24.2
- EPS (TTM)
- $7.96
- Dividend yield
- 1.33%
Volume 0.10M
Average 0.12M
NHC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
National HealthCare CorporationAMEX: NHC
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How NHC compares with its peers on the latest reported figures
- NHC's LTM Sep 2026 research & development of $0 is the highest of the 10 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for NHC, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NHC) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for NHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.01B | 1.07B | 1.14B | 1.3B | 1.52B |
| Cost of Revenue | 666.06M | 686.17M | 712.34M | 810.93M | 921.08M |
| Gross Profit | 344.88M | 388.11M | 429.2M | 487.01M | 596.7M |
| Gross Margin | 34.1% | 36.1% | 37.6% | 37.5% | 39.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 40.82M | 40.98M | 41.53M | 43.18M | 46.23M |
| Operating Expenses | 293.95M | 356.22M | 372.07M | 401.25M | 468.35M |
| Depreciation & Amortization | 40.67M | 40.49M | 42.03M | 41.99M | 44.92M |
| EBITDA | 191.56M | 68.28M | 131.1M | 182.53M | 213.72M |
| EBITDA Margin | 18.9% | 6.4% | 11.5% | 14.1% | 14.1% |
| Operating Income | 50.93M | 31.9M | 57.13M | 85.76M | 128.35M |
| Operating Margin | 5.0% | 3.0% | 5.0% | 6.6% | 8.5% |
| Interest Income | 4.67M | 5.13M | 8.38M | 10.1M | 9.84M |
| Interest Expense | 845K | 563K | 324K | 4.14M | 6.37M |
| Other Income / Expenses | 99.11M | (4.67M) | 31.6M | 50.65M | 34.08M |
| Income Before Tax | 150.04M | 27.23M | 88.74M | 136.41M | 162.43M |
| Pre-Tax Margin | 14.8% | 2.5% | 7.8% | 10.5% | 10.7% |
| Income Tax Expense | 10.95M | 7.25M | 23.45M | 34.32M | 39.83M |
| Net Income | 138.59M | 22.45M | 66.8M | 101.93M | 120.02M |
| Net Margin | 13.7% | 2.1% | 5.9% | 7.9% | 7.9% |
| EPS (Basic) | 9.03 | 1.46 | 4.36 | 6.62 | 7.76 |
| EPS (Diluted) | 8.99 | 1.45 | 4.34 | 6.53 | 7.67 |
| Weighted Avg Shares | 15.35M | 15.41M | 15.31M | 15.39M | 15.47M |
| Weighted Avg Shares (Diluted) | 15.42M | 15.45M | 15.38M | 15.6M | 15.65M |
National HealthCare Corporation
AMEX:NHC
Intrinsic Alpha fair value
Locked
Current Price
$201.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.